Catalyst Dossier · compiled by CeliA 🧫

Bausch Health Companies Inc. (BHC)

Pharmaceutical Preparations · market cap $1.8B · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Bausch Health Companies Inc. (BHC) is a diversified Canadian pharmaceutical company with ~$10.3B in 2025 revenue spanning gastroenterology, dermatology, neuroscience, and international pharmaceuticals. The company carries an extremely heavy debt load of ~$20.4B in net debt against a market cap of ~$1.8B, making the equity essentially a leveraged stub. An upcoming earnings catalyst is scheduled for July 29, 2026.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Viramidine	Phase 3	Chronic Hepatitis C
IDP 121 Lotion	Phase 3	Acne
SP-333 1 mg	Phase 2	Constipation
IDP-118 Vehicle Cream	Phase 2	Psoriasis
Larsucosterol	Phase 3	Hepatitis
Bisacodyl	Phase 3	Chronic Idiopathic Constipation
IDP-121 Lotion	Phase 3	Acne
SC MNTX	Phase 2	Bowel Dysfunction
pradefovir mesylate	Phase 2	Hepatitis B, Chronic
Low Dose Rifaximin ER	Phase 2	Sickle Cell Disease
open-label rifaximin	Phase 3	Irritable Bowel Syndrome With Diarrhea
Plecanatide	Phase 3	Chronic Idiopathic Constipation
5 ASA, enemas, suppositories, corticosteroids	Phase 3	Ulcerative Colitis
ACYC	Phase 3	Acne
Retigabine	Phase 2	Postherpetic Neuralgia
IDP-126 Gel	Phase 3	Acne Vulgaris
SAN-300 0.5 mg/kg QW	Phase 2	Rheumatoid Arthritis
IDP-118 Lotion	Phase 3	Plaque Psoriasis
IDP-124 Lotion	Phase 3	Atopic Dermatitis
IDP-124 Vehicle Lotion	Phase 3	Atopic Dermatitis

Price & technical context

3-month

-19.0%

6-month

-22.1%

12-month

-33.7%

52-wk range

$4.43–$8.34

vs 50-day MA

-9.3%

vs 200-day MA

-22.7%

Realized vol

54.7%

Max drawdown

-55.8%

Daily closes through 2026-07-28. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for BHC (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.